SCHEDULE 13G: Empery Asset Management Discloses 9.96% Stake in Tenaya Therapeutics

Empery Asset Management, LP, along with Ryan M. Lane and Martin D. Hoe, has disclosed a collective beneficial ownership of 9.96% in Tenaya Therapeutics, Inc. as of March 31, 2025.

Summary

• Empery Asset Management, LP, Ryan M. Lane, and Martin D. Hoe (collectively, the "Reporting Persons") have filed a Schedule 13G indicating beneficial ownership in Tenaya Therapeutics, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 8,727,314 shares of Tenaya Therapeutics, Inc. Common Stock.
• This ownership represents 9.96% of the company's outstanding Common Stock.
• The percentage is calculated based on 87,582,646 shares of Common Stock outstanding as of March 4, 2025, as reported in Tenaya Therapeutics' Annual Report on Form 10-K filed on March 10, 2025.
• Empery Asset Management, LP serves as the investment manager for the funds holding these shares (the "Empery Funds").
• Ryan M. Lane and Martin D. Hoe, as Managing Members of the General Partner of the Investment Manager, are deemed to be beneficial owners of the shares held by the Empery Funds.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. The acquisition of a significant stake by an institutional investor is generally viewed positively as it indicates confidence, but the document itself does not contain performance metrics or forward-looking statements to assess financial sentiment beyond the fact of the investment.

Positives

• A significant institutional investor, Empery Asset Management, has taken a substantial stake (9.96%) in Tenaya Therapeutics, indicating potential confidence in the company's long-term prospects.
• The acquisition of shares was stated to be in the ordinary course of business, suggesting a strategic investment rather than an activist play aimed at control.

Risks

• The document does not detail specific risks related to Tenaya Therapeutics' operations or financial performance, as it is a beneficial ownership disclosure.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Tenaya Therapeutics, Inc. or the Reporting Persons regarding the company's future performance.

Industry Context

The filing indicates a significant institutional investment in Tenaya Therapeutics, a biotechnology company. Such investments can signal investor confidence in the company's pipeline, market position, or future growth potential within the competitive biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and attracting further investment.
• Company Management: Awareness of a large institutional holder may influence strategic decisions or communication strategies, though the filing states no intent to influence control.

Key Dates

Keywords

Tenaya Therapeutics, Empery Asset Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals, SEC Filing